Trials / Completed
CompletedNCT00091793
Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis
A Randomized, Double-Blind Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 332 (actual)
- Sponsor
- Amgen · Industry
- Sex
- Female
- Age
- 90 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine whether treatment with AMG 162 can prevent lumbar spine bone loss in both early and late postmenopausal women with osteopenia, and to further test the safety and tolerability of AMG 162 in this population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 162 | 60 mg/mL denosumab given day 1, month 6, month 12 and month 18 |
| DRUG | Placebo | Placebo given at day 1, month 6, month 12 and month 18 |
Timeline
- Start date
- 2004-08-01
- Primary completion
- 2009-02-01
- Completion
- 2009-03-01
- First posted
- 2004-09-21
- Last updated
- 2010-12-31
- Results posted
- 2010-01-26
Source: ClinicalTrials.gov record NCT00091793. Inclusion in this directory is not an endorsement.